A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.

MLA

Ho Won Kang, et al. “A Novel Urinary MRNA Signature Using the Droplet Digital Polymerase Chain Reaction Platform Improves Discrimination between Prostate Cancer and Benign Prostatic Hyperplasia within the Prostate-Specific Antigen Gray Zone.” Investigative & Clinical Urology, vol. 61, no. 4, July 2020, pp. 411–18. EBSCOhost, https://doi.org/10.4111/icu.2020.61.4.411.

APA

Ho Won Kang, Hee Youn Lee, Young Joon Byun, Pildu Jeong, Jin Sun Yoon, Dong Ho Kim, Won Tae Kim, Yong-June Kim, Sang-Cheol Lee, Seok Joong Yun, & Wun-Jae Kim. (2020). A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone. Investigative & Clinical Urology, 61(4), 411–418. https://doi.org/10.4111/icu.2020.61.4.411

Chicago

Ho Won Kang, Hee Youn Lee, Young Joon Byun, Pildu Jeong, Jin Sun Yoon, Dong Ho Kim, Won Tae Kim, et al. 2020. “A Novel Urinary MRNA Signature Using the Droplet Digital Polymerase Chain Reaction Platform Improves Discrimination between Prostate Cancer and Benign Prostatic Hyperplasia within the Prostate-Specific Antigen Gray Zone.” Investigative & Clinical Urology 61 (4): 411–18. doi:10.4111/icu.2020.61.4.411.